HER2 Staining of Breast Cancer is Reduced under the Current Protocol of Ventana PATHWAY Anti-Her-2/neu (4B5).

Pathology InternationalVolume 74, Issue 2 p. 99-101 LETTER TO THE EDITOR HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5) Yoshiya Horimoto, Yoshiya Horimoto orcid.org/0000-0001-8935-0768 Department of Human Pathology, Faculty of Medicine, Juntendo University, Tokyo, Japan Department of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, JapanSearch for more papers by this authorHiroko Onagi, Hiroko Onagi Department of Human Pathology, Faculty of Medicine, Juntendo University, Tokyo, JapanSearch for more papers by this authorJunichiro Watanabe, Junichiro Watanabe Department of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, JapanSearch for more papers by this authorTakuo Hayashi, Takuo Hayashi orcid.org/0000-0002-8544-9370 Department of Human Pathology, Faculty of Medicine, Juntendo University, Tokyo, Japan Department of Diagnostic Pathology, Juntendo University Hospital, Tokyo, JapanSearch for more papers by this author Yoshiya Horimoto, Yoshiya Horimoto orcid.org/0000-0001-8935-0768 Department of Human Pathology, Faculty of Medicine, Juntendo University, Tokyo, Japan Department of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, JapanSearch for more papers by this authorHiroko Onagi, Hiroko Onagi Department of Human Pathology, Faculty of Medicine, Juntendo University, Tokyo, JapanSearch for more papers by this authorJunichiro Watanabe, Junichiro Watanabe Department of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, JapanSearch for more papers by this authorTakuo Hayashi, Takuo Hayashi orcid.org/0000-0002-8544-9370 Department of Human Pathology, Faculty of Medicine, Juntendo University, Tokyo, Japan Department of Diagnostic Pathology, Juntendo University Hospital, Tokyo, JapanSearch for more papers by this author First published: 10 January 2024 https://doi.org/10.1111/pin.13404Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010; 28: 4307–4315. 10.1200/JCO.2009.26.2154 PubMedWeb of Science®Google Scholar 2Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367: 1783–1791. 10.1056/NEJMoa1209124 CASPubMedWeb of Science®Google Scholar 3Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022; 387: 9–20. 10.1056/NEJMoa2203690 CASPubMedWeb of Science®Google Scholar 4Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36: 2105–2122. 10.1200/JCO.2018.77.8738 CASPubMedWeb of Science®Google Scholar 5Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology–College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2023; 147(9): 993–1000. 10.5858/arpa.2023-0950-SA PubMedWeb of Science®Google Scholar Volume74, Issue2February 2024Pages 99-101 ReferencesRelatedInformation